Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
| Autor: | Elena Castro, Carlo Cattrini, Melissa Bersanelli, Alessia Mennitto, David Olmos, David Lorente, Alessandra Gennari, Rodrigo España |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Review chemotherapy Olaparib chemistry.chemical_compound Prostate cancer ipatasertib nonmetastatic castration-resistant prostate cancer LuPSMA Internal medicine medicine Enzalutamide metastatic hormone-naïve prostate cancer PARP inhibitors RC254-282 business.industry metastatic hormone-sensitive prostate cancer Apalutamide Abiraterone acetate Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Darolutamide chemistry Docetaxel metastatic castration-resistant prostate cancer Cabazitaxel business medicine.drug androgen-receptor signaling inhibitors |
| Zdroj: | Cancers, Vol 13, Iss 4522, p 4522 (2021) Cancers |
| Popis: | Simple Summary Several strategies have demonstrated the ability to improve the survival of patients with both metastatic and nonmetastatic prostate cancer. The old backbone of androgen-deprivation monotherapy has been disrupted in the hormone-sensitive setting, and several options have been introduced for the management of the castration-resistant disease. However, no optimal sequencing is still defined, and few randomized comparisons are currently available to identify the approach that maximizes the long-term benefit for these patients. This comprehensive review aims at resuming the current evidence on this topic to help physicians during the treatment choice for patients with advanced prostate cancer. Abstract The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177–PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|